These are the stocks posting the largest moves before the bell.Market Insiderread more
May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
Analyst Michael Olson says he has "a high degree of confidence" that Amazon shares can reach the level without "significant changes to the business."Investingread more
House Judiciary Committee Chairman Jerry Nadler says Mueller told the committee he would make his opening statement before the public.Politicsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Breaking up the social network won't lead to better data protection, said former Facebook executive Chris Kelly.Technologyread more
A downgrade from BMO analysts led to an unsavory drop in Chipotle's stock, and some analysts are advising waiting out the weakness.Trading Nationread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
Sears opens its first Home & Life stores and plans to open more as it looks for a fresh start after bankruptcy.Retailread more
New orders for U.S.-made capital goods fell more than expected in April, further evidence that manufacturing and the broader economy were slowing.Economyread more
A recent survey found that 23% of Americans say that paying for basic necessities such as rent, utilities and food contributes the most to their credit card debt.Make It - Become Debt-Freeread more
J.P. Morgan alerted clients to two biotech companies that it believes could outperform peers in the next year.
Though bullish biotech as a whole, analysts at the firm announced that they were upgrading a pair of stocks to overweight.
"Overall, we remain optimistic about the outlook for biotech in 2018, despite recent volatility giving back some early outperformance to start the year," wrote analyst Cory Kasimov on Wednesday. "Indeed, the combination of continued innovation, a constructive FDA, and ready access to capital markets, all under the auspices of an omnipresent M&A backdrop, presents a compelling setup."
Here are the two stocks J.P. Morgan upgraded to overweight during the firm's ongoing rating rebalancing.